Drug survival of adalimumab biosimilar vs adalimumab originator in hidradenitis suppurativa: Can equivalence be assumed? A retrospective cohort study

J Eur Acad Dermatol Venereol. 2023 May;37(5):e678-e680. doi: 10.1111/jdv.18801. Epub 2022 Dec 15.

Authors

Mercè Grau-Pérez¹, Laura Rodríguez-Aguilar², Gaston Roustan^{1

2}, Fernando Alfageme^{1

2}

Affiliations

¹ Dermatology Department, Hospital Universitario Puerta de Hierro, Majadahonda, Spain.
² Medical School, Universidad Autónoma de Madrid, Madrid, Spain.

PMID: 36461770
DOI: 10.1111/jdv.18801

No abstract available

Publication types

Letter

MeSH terms

Adalimumab / therapeutic use
Biosimilar Pharmaceuticals* / therapeutic use
Hidradenitis Suppurativa* / drug therapy
Humans
Retrospective Studies
Treatment Outcome

Substances

Adalimumab
Biosimilar Pharmaceuticals